
51 - 200 employés
Fondée en 2004
🧬 Biotechnologie
💊 Pharmaceutique
💰 €75 000 000 Post IPO equity en 2024-02
Biotechnology • Pharmaceuticals
Liquidia est une entreprise biopharmaceutique se concentrant sur le développement de thérapies inhalées pour les maladies cardiopulmonaires rares, en particulier l'hypertension artérielle pulmonaire (HTAP) et l'hypertension pulmonaire associée à une maladie pulmonaire interstitielle (HP-MPI). La société s'appuie sur sa technologie propriétaire d'ingénierie de particules PRINT® pour créer des formulations et des méthodes de livraison exclusives visant à améliorer l'efficacité, la tolérance et la commodité des médicaments inhalés ; son portefeuille comprend le trépostinil inhalé (produit commercial) et des candidats en phase clinique comme le L606. Liquidia met l'accent sur le soutien aux patients, le développement clinique et la progression des thérapies pour de meilleurs résultats respiratoires.
🕒 il y a 2 mois
🗣️🇺🇸🇬🇧 Anglais requis
Améliorez vos chances d'obtenir un entretien en vérifiant votre score de CV avant de postuler.

51 - 200 employés
Fondée en 2004
🧬 Biotechnologie
💊 Pharmaceutique
💰 €75 000 000 Post IPO equity en 2024-02
Biotechnology • Pharmaceuticals
Liquidia est une entreprise biopharmaceutique se concentrant sur le développement de thérapies inhalées pour les maladies cardiopulmonaires rares, en particulier l'hypertension artérielle pulmonaire (HTAP) et l'hypertension pulmonaire associée à une maladie pulmonaire interstitielle (HP-MPI). La société s'appuie sur sa technologie propriétaire d'ingénierie de particules PRINT® pour créer des formulations et des méthodes de livraison exclusives visant à améliorer l'efficacité, la tolérance et la commodité des médicaments inhalés ; son portefeuille comprend le trépostinil inhalé (produit commercial) et des candidats en phase clinique comme le L606. Liquidia met l'accent sur le soutien aux patients, le développement clinique et la progression des thérapies pour de meilleurs résultats respiratoires.
• Direct Commercial new product planning and lifecycle strategy. Provide input into future product development, specifically L606 BID Treprostinil. Integrate global market insights, financial opportunity, and portfolio strategy to optimize future commercial opportunity • Shape upstream clinical development strategy for Phase III and IV studies. Translate unmet needs and financial value into endpoint/label discussions, patient population strategy, and evidence-generation plans to maximize future label strength and access potential • Participate in the annual Brand Planning process for Yutrepia, establishing positioning, core messaging, and strategic objectives across HCP, patient, and payer stakeholders • Track market intelligence for the PH landscape, monitoring market volume and share trends, competitor pipelines. Synthesize insights into decision-ready recommendations • Perform market research to support brand planning, new product planning, and input into clinical development • Act as the commercial voice on cross-functional product teams for programs in development. Integrate with Medical Affairs, Regulatory, Market Access, Commercial Analytics, Finance, and Business Development
• Education and Experience • - Bachelor’s degree required in Marketing, Business, Life Sciences, or a related field • - 10+ years of progressive experience in pharmaceutical or biotechnology commercial roles • - Significant experience in strategic marketing, commercial strategy, brand management, and/or new product planning • - Experience in rare disease, especially Pulmonary Hypertension, is a plus • Knowledge, Skills, and Abilities • - Deep understanding of pharmaceutical commercialization, including brand strategy, lifecycle management, new product planning • - Strong understanding of clinical development processes, evidence-generation strategies, labeling considerations, and regulatory pathways. • - Analytical and insights capabilities—proficiency in interpreting qualitative and quantitative market research, competitive intelligence, and performance analytics • - Financial acumen—comfort with forecasting models, scenario planning, and business case development for lifecycle or pipeline investments • - Ability to thrive in small company environment
• Liquidia offers a competitive compensation package as well as a comprehensive benefits package that includes Medical, Dental, Vision, STD, LTD, 401(k) Savings Retirement Plan, ESPP, and more!
Postuler Maintenant🕒 il y a 2 mois
EHS director leading occupational health and safety across START’s oncology clinical research sites. Standardizing compliance, incident response, training, and risk reduction nationwide.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 2 mois
Director of Corporate Partnership Engagement responsible for sourcing and executing offtake opportunities with corporate buyers. Supporting energy solutions across solar, battery storage, and gas generation sectors.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 2 mois
Agentic Workspace Solution Director at Genpact designing Microsoft-based solutions for modern workspaces. Leading projects and sales enablement with a focus on employee experience and productivity.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 2 mois
Adobe Solutions Director crafting innovative proposals for Adobe Experience Cloud solutions. Collaborating with clients and leading teams to deliver impactful results and high client satisfaction.
🗣️🇺🇸🇬🇧 Anglais requis
🕒 il y a 2 mois
Director of Acquisition managing growth strategies for a sports and gaming app. Collaborating with multiple teams to drive new customer acquisition and optimize performance.
🗣️🇺🇸🇬🇧 Anglais requis